Boston Scientific Corporation Logo

Boston Scientific Corporation

BSX-PA

(1.5)
Stock Price

122,18 USD

10.55% ROA

8.91% ROE

69.17x PER

Market Cap.

126.410.559.200,00 USD

51.87% DER

0% Yield

11.24% NPM

Boston Scientific Corporation Stock Analysis

Boston Scientific Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Boston Scientific Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (47%), which means it has a small amount of debt compared to the ownership it holds

2 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

3 ROE

ROE in an average range (6.77%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (8.42%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 PBV

The stock's elevated P/BV ratio (4.21x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-537), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Boston Scientific Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Boston Scientific Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Boston Scientific Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Boston Scientific Corporation Revenue
Year Revenue Growth
1991 230.000.000
1992 315.200.000 27.03%
1993 380.100.000 17.07%
1994 448.900.000 15.33%
1995 1.107.000.000 59.45%
1996 1.462.000.000 24.28%
1997 1.872.300.000 21.91%
1998 2.233.600.000 16.18%
1999 2.842.000.000 21.41%
2000 2.664.000.000 -6.68%
2001 2.673.000.000 0.34%
2002 2.919.000.000 8.43%
2003 3.476.000.000 16.02%
2004 5.624.000.000 38.19%
2005 6.283.000.000 10.49%
2006 7.821.000.000 19.67%
2007 8.357.000.000 6.41%
2008 8.050.000.000 -3.81%
2009 8.188.000.000 1.69%
2010 7.806.000.000 -4.89%
2011 7.622.000.000 -2.41%
2012 7.249.000.000 -5.15%
2013 7.143.000.000 -1.48%
2014 7.380.000.000 3.21%
2015 7.477.000.000 1.3%
2016 8.386.000.000 10.84%
2017 9.048.000.000 7.32%
2018 9.823.000.000 7.89%
2019 10.735.000.000 8.5%
2020 9.913.000.000 -8.29%
2021 11.888.000.000 16.61%
2022 12.682.000.000 6.26%
2023 14.108.000.000 10.11%
2023 14.240.000.000 0.93%
2024 16.480.000.000 13.59%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Boston Scientific Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1991 0
1992 0 0%
1993 0 0%
1994 29.500.000 100%
1995 0 0%
1996 0 0%
1997 196.700.000 100%
1998 882.200.000 77.7%
1999 197.000.000 -347.82%
2000 199.000.000 1.01%
2001 275.000.000 27.64%
2002 343.000.000 19.83%
2003 452.000.000 24.12%
2004 569.000.000 20.56%
2005 680.000.000 16.32%
2006 1.008.000.000 32.54%
2007 1.091.000.000 7.61%
2008 1.006.000.000 -8.45%
2009 1.035.000.000 2.8%
2010 939.000.000 -10.22%
2011 895.000.000 -4.92%
2012 886.000.000 -1.02%
2013 861.000.000 -2.9%
2014 817.000.000 -5.39%
2015 876.000.000 6.74%
2016 920.000.000 4.78%
2017 997.000.000 7.72%
2018 1.113.000.000 10.42%
2019 1.174.000.000 5.2%
2020 1.143.000.000 -2.71%
2021 1.204.000.000 5.07%
2022 1.323.000.000 8.99%
2023 1.424.000.000 7.09%
2023 1.414.000.000 -0.71%
2024 1.532.000.000 7.7%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Boston Scientific Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1991 77.700.000
1992 105.900.000 26.63%
1993 131.200.000 19.28%
1994 127.200.000 -3.14%
1995 505.000.000 74.81%
1996 719.200.000 29.78%
1997 710.400.000 -1.24%
1998 786.300.000 9.65%
1999 842.000.000 6.62%
2000 867.000.000 2.88%
2001 961.000.000 9.78%
2002 1.002.000.000 4.09%
2003 1.171.000.000 14.43%
2004 1.742.000.000 32.78%
2005 1.814.000.000 3.97%
2006 2.675.000.000 32.19%
2007 2.909.000.000 8.04%
2008 2.792.000.000 -4.19%
2009 4.848.000.000 42.41%
2010 2.765.000.000 -75.33%
2011 2.659.000.000 -3.99%
2012 2.535.000.000 -4.89%
2013 2.674.000.000 5.2%
2014 2.902.000.000 7.86%
2015 2.873.000.000 -1.01%
2016 3.099.000.000 7.29%
2017 3.294.000.000 5.92%
2018 3.569.000.000 7.71%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Boston Scientific Corporation EBITDA
Year EBITDA Growth
1991 73.700.000
1992 95.800.000 23.07%
1993 112.000.000 14.46%
1994 138.100.000 18.9%
1995 516.000.000 73.24%
1996 436.800.000 -18.13%
1997 643.400.000 32.11%
1998 -108.500.000 693%
1999 952.000.000 111.4%
2000 934.000.000 -1.93%
2001 893.000.000 -4.59%
2002 896.000.000 0.33%
2003 1.044.000.000 14.18%
2004 2.265.000.000 53.91%
2005 2.828.000.000 19.91%
2006 6.519.000.000 56.62%
2007 2.559.000.000 -154.75%
2008 -915.000.000 379.67%
2009 -287.000.000 -218.82%
2010 1.503.000.000 119.1%
2011 2.132.000.000 29.5%
2012 1.348.000.000 -58.16%
2013 1.275.000.000 -5.73%
2014 1.348.000.000 5.42%
2015 1.446.000.000 6.78%
2016 1.827.000.000 20.85%
2017 1.973.000.000 7.4%
2018 2.415.000.000 18.3%
2019 2.082.000.000 -15.99%
2020 1.833.000.000 -13.58%
2021 2.784.000.000 34.16%
2022 2.800.000.000 0.57%
2023 3.204.000.000 12.61%
2023 3.620.000.000 11.49%
2024 4.232.000.000 14.46%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Boston Scientific Corporation Gross Profit
Year Gross Profit Growth
1991 151.600.000
1992 203.300.000 25.43%
1993 246.200.000 17.42%
1994 295.800.000 16.77%
1995 830.000.000 64.36%
1996 1.122.400.000 26.05%
1997 1.408.600.000 20.32%
1998 1.574.700.000 10.55%
1999 1.942.000.000 18.91%
2000 1.922.000.000 -1.04%
2001 1.754.000.000 -9.58%
2002 2.049.000.000 14.4%
2003 2.515.000.000 18.53%
2004 4.332.000.000 41.94%
2005 4.897.000.000 11.54%
2006 5.614.000.000 12.77%
2007 6.015.000.000 6.67%
2008 5.581.000.000 -7.78%
2009 5.612.000.000 0.55%
2010 5.207.000.000 -7.78%
2011 4.963.000.000 -4.92%
2012 4.747.000.000 -4.55%
2013 4.829.000.000 1.7%
2014 5.059.000.000 4.55%
2015 5.234.000.000 3.34%
2016 5.883.000.000 11.03%
2017 6.387.000.000 7.89%
2018 6.940.000.000 7.97%
2019 7.554.000.000 8.13%
2020 6.403.000.000 -17.98%
2021 8.128.000.000 21.22%
2022 8.679.000.000 6.35%
2023 9.660.000.000 10.16%
2023 9.895.000.000 2.37%
2024 10.340.000.000 4.3%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Boston Scientific Corporation Net Profit
Year Net Profit Growth
1991 41.800.000
1992 56.600.000 26.15%
1993 69.700.000 18.79%
1994 79.700.000 12.55%
1995 8.000.000 -896.25%
1996 167.100.000 95.21%
1997 139.300.000 -19.96%
1998 -264.400.000 152.69%
1999 371.000.000 171.27%
2000 373.000.000 0.54%
2001 -54.000.000 790.74%
2002 373.000.000 114.48%
2003 472.000.000 20.97%
2004 1.062.000.000 55.56%
2005 628.000.000 -69.11%
2006 -3.577.000.000 117.56%
2007 -495.000.000 -622.63%
2008 -2.072.000.000 76.11%
2009 -1.025.000.000 -102.15%
2010 -1.065.000.000 3.76%
2011 441.000.000 341.5%
2012 -4.068.000.000 110.84%
2013 -121.000.000 -3261.98%
2014 267.000.000 145.32%
2015 -239.000.000 211.72%
2016 347.000.000 168.88%
2017 104.000.000 -233.65%
2018 1.671.000.000 93.78%
2019 4.700.000.000 64.45%
2020 -140.000.000 3457.14%
2021 1.041.000.000 113.45%
2022 698.000.000 -49.14%
2023 2.016.000.000 65.38%
2023 1.593.000.000 -26.55%
2024 1.296.000.000 -22.92%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Boston Scientific Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1991 0
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 1 0%
2004 1 100%
2005 1 0%
2006 -3 100%
2007 0 0%
2008 -1 100%
2009 -1 0%
2010 -1 0%
2011 0 0%
2012 -3 100%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 1 100%
2019 3 66.67%
2020 0 0%
2021 1 0%
2022 0 0%
2023 1 100%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Boston Scientific Corporation Free Cashflow
Year Free Cashflow Growth
1991 22.300.000
1992 32.100.000 30.53%
1993 30.000.000 -7%
1994 32.000.000 6.25%
1995 -44.000.000 172.73%
1996 -1.000.000 -4300%
1997 -157.700.000 99.37%
1998 -1.975.500.000 92.02%
1999 647.000.000 405.33%
2000 663.000.000 2.41%
2001 369.000.000 -79.67%
2002 624.000.000 40.87%
2003 599.000.000 -4.17%
2004 1.530.000.000 60.85%
2005 562.000.000 -172.24%
2006 1.504.000.000 62.63%
2007 571.000.000 -163.4%
2008 854.000.000 33.14%
2009 473.000.000 -80.55%
2010 47.000.000 -906.38%
2011 704.000.000 93.32%
2012 1.034.000.000 31.91%
2013 837.000.000 -23.54%
2014 1.010.000.000 17.13%
2015 353.000.000 -186.12%
2016 596.000.000 40.77%
2017 1.107.000.000 46.16%
2018 -6.000.000 18550%
2019 1.375.000.000 100.44%
2020 1.132.000.000 -21.47%
2021 1.316.000.000 13.98%
2022 914.000.000 -43.98%
2023 492.000.000 -85.77%
2023 1.703.000.000 71.11%
2024 658.000.000 -158.81%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Boston Scientific Corporation Operating Cashflow
Year Operating Cashflow Growth
1991 29.600.000
1992 42.500.000 30.35%
1993 65.800.000 35.41%
1994 67.800.000 2.95%
1995 25.000.000 -171.2%
1996 134.300.000 81.38%
1997 80.500.000 -66.83%
1998 258.500.000 68.86%
1999 727.000.000 64.44%
2000 739.000.000 1.62%
2001 490.000.000 -50.82%
2002 736.000.000 33.42%
2003 787.000.000 6.48%
2004 1.804.000.000 56.37%
2005 903.000.000 -99.78%
2006 1.845.000.000 51.06%
2007 934.000.000 -97.54%
2008 1.216.000.000 23.19%
2009 835.000.000 -45.63%
2010 325.000.000 -156.92%
2011 1.008.000.000 67.76%
2012 1.260.000.000 20%
2013 1.082.000.000 -16.45%
2014 1.269.000.000 14.74%
2015 600.000.000 -111.5%
2016 972.000.000 38.27%
2017 1.426.000.000 31.84%
2018 310.000.000 -360%
2019 1.836.000.000 83.12%
2020 1.508.000.000 -21.75%
2021 1.870.000.000 19.36%
2022 1.526.000.000 -22.54%
2023 698.000.000 -118.62%
2023 2.503.000.000 72.11%
2024 813.000.000 -207.87%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Boston Scientific Corporation Capital Expenditure
Year Capital Expenditure Growth
1991 7.300.000
1992 10.400.000 29.81%
1993 35.800.000 70.95%
1994 35.800.000 0%
1995 69.000.000 48.12%
1996 135.300.000 49%
1997 238.200.000 43.2%
1998 2.234.000.000 89.34%
1999 80.000.000 -2692.5%
2000 76.000.000 -5.26%
2001 121.000.000 37.19%
2002 112.000.000 -8.04%
2003 188.000.000 40.43%
2004 274.000.000 31.39%
2005 341.000.000 19.65%
2006 341.000.000 0%
2007 363.000.000 6.06%
2008 362.000.000 -0.28%
2009 362.000.000 0%
2010 278.000.000 -30.22%
2011 304.000.000 8.55%
2012 226.000.000 -34.51%
2013 245.000.000 7.76%
2014 259.000.000 5.41%
2015 247.000.000 -4.86%
2016 376.000.000 34.31%
2017 319.000.000 -17.87%
2018 316.000.000 -0.95%
2019 461.000.000 31.45%
2020 376.000.000 -22.61%
2021 554.000.000 32.13%
2022 612.000.000 9.48%
2023 206.000.000 -197.09%
2023 800.000.000 74.25%
2024 155.000.000 -416.13%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Boston Scientific Corporation Equity
Year Equity Growth
1991 90.300.000
1992 249.100.000 63.75%
1993 246.700.000 -0.97%
1994 340.000.000 27.44%
1995 753.000.000 54.85%
1996 916.300.000 17.82%
1997 986.200.000 7.09%
1998 821.100.000 -20.11%
1999 1.724.000.000 52.37%
2000 1.935.000.000 10.9%
2001 2.015.000.000 3.97%
2002 2.467.000.000 18.32%
2003 2.862.000.000 13.8%
2004 4.025.000.000 28.89%
2005 4.282.000.000 6%
2006 15.298.000.000 72.01%
2007 15.097.000.000 -1.33%
2008 13.138.000.000 -14.91%
2009 12.301.000.000 -6.8%
2010 11.296.000.000 -8.9%
2011 11.353.000.000 0.5%
2012 6.870.000.000 -65.25%
2013 6.539.000.000 -5.06%
2014 6.843.000.000 4.44%
2015 6.320.000.000 -8.28%
2016 6.733.000.000 6.13%
2017 7.011.000.000 3.97%
2018 8.725.000.000 19.64%
2019 13.877.000.000 37.13%
2020 15.327.000.000 9.46%
2021 16.623.000.000 7.8%
2022 17.574.000.000 5.41%
2023 19.529.000.000 10.01%
2023 19.128.000.000 -2.1%
2024 20.609.000.000 7.19%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Boston Scientific Corporation Assets
Year Assets Growth
1991 137.400.000
1992 299.100.000 54.06%
1993 323.200.000 7.46%
1994 431.800.000 25.15%
1995 1.075.000.000 59.83%
1996 1.512.100.000 28.91%
1997 1.967.800.000 23.16%
1998 3.892.700.000 49.45%
1999 3.572.000.000 -8.98%
2000 3.427.000.000 -4.23%
2001 3.974.000.000 13.76%
2002 4.450.000.000 10.7%
2003 5.699.000.000 21.92%
2004 8.170.000.000 30.24%
2005 8.196.000.000 0.32%
2006 31.096.000.000 73.64%
2007 31.197.000.000 0.32%
2008 27.080.000.000 -15.2%
2009 25.177.000.000 -7.56%
2010 22.128.000.000 -13.78%
2011 21.290.000.000 -3.94%
2012 17.154.000.000 -24.11%
2013 16.734.000.000 -2.51%
2014 16.830.000.000 0.57%
2015 18.133.000.000 7.19%
2016 18.096.000.000 -0.2%
2017 19.041.000.000 4.96%
2018 20.998.000.000 9.32%
2019 30.565.000.000 31.3%
2020 30.778.000.000 0.69%
2021 32.230.000.000 4.51%
2022 32.470.000.000 0.74%
2023 35.136.000.000 7.59%
2023 34.043.000.000 -3.21%
2024 37.108.000.000 8.26%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Boston Scientific Corporation Liabilities
Year Liabilities Growth
1991 47.100.000
1992 50.000.000 5.8%
1993 76.500.000 34.64%
1994 91.800.000 16.67%
1995 322.000.000 71.49%
1996 595.800.000 45.96%
1997 981.600.000 39.3%
1998 3.071.600.000 68.04%
1999 1.848.000.000 -66.21%
2000 1.492.000.000 -23.86%
2001 1.959.000.000 23.84%
2002 1.983.000.000 1.21%
2003 2.837.000.000 30.1%
2004 4.145.000.000 31.56%
2005 3.914.000.000 -5.9%
2006 15.798.000.000 75.22%
2007 16.100.000.000 1.88%
2008 13.942.000.000 -15.48%
2009 12.876.000.000 -8.28%
2010 10.832.000.000 -18.87%
2011 9.937.000.000 -9.01%
2012 10.284.000.000 3.37%
2013 10.195.000.000 -0.87%
2014 9.987.000.000 -2.08%
2015 11.813.000.000 15.46%
2016 11.363.000.000 -3.96%
2017 12.030.000.000 5.54%
2018 12.273.000.000 1.98%
2019 16.688.000.000 26.46%
2020 15.451.000.000 -8.01%
2021 15.607.000.000 1%
2022 14.896.000.000 -4.77%
2023 15.606.000.000 4.55%
2023 14.914.000.000 -4.64%
2024 16.498.000.000 9.6%

Boston Scientific Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
10.35
Net Income per Share
1.24
Price to Earning Ratio
69.17x
Price To Sales Ratio
8.3x
POCF Ratio
47.96
PFCF Ratio
71.87
Price to Book Ratio
6.2
EV to Sales
8.82
EV Over EBITDA
34.66
EV to Operating CashFlow
51.05
EV to FreeCashFlow
76.38
Earnings Yield
0.01
FreeCashFlow Yield
0.01
Market Cap
126,41 Bil.
Enterprise Value
134,36 Bil.
Graham Number
19.67
Graham NetNet
-7.08

Income Statement Metrics

Net Income per Share
1.24
Income Quality
1.44
ROE
0.09
Return On Assets
0.05
Return On Capital Employed
0.09
Net Income per EBT
0.81
EBT Per Ebit
0.8
Ebit per Revenue
0.17
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.67
Operating Profit Margin
0.17
Pretax Profit Margin
0.14
Net Profit Margin
0.11

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.79
Free CashFlow per Share
1.2
Capex to Operating CashFlow
0.33
Capex to Revenue
0.06
Capex to Depreciation
0.71
Return on Invested Capital
0.07
Return on Tangible Assets
0.11
Days Sales Outstanding
57.53
Days Payables Outstanding
66.1
Days of Inventory on Hand
190.27
Receivables Turnover
6.35
Payables Turnover
5.52
Inventory Turnover
1.92
Capex per Share
0.59

Balance Sheet

Cash per Share
2,03
Book Value per Share
14,01
Tangible Book Value per Share
0.54
Shareholders Equity per Share
13.85
Interest Debt per Share
7.37
Debt to Equity
0.52
Debt to Assets
0.28
Net Debt to EBITDA
2.05
Current Ratio
1.61
Tangible Asset Value
0,80 Bil.
Net Current Asset Value
-7,51 Bil.
Invested Capital
26596000000
Working Capital
3,42 Bil.
Intangibles to Total Assets
0.53
Average Receivables
2,35 Bil.
Average Payables
0,91 Bil.
Average Inventory
2584500000
Debt to Market Cap
0.08

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Boston Scientific Corporation Dividends
Year Dividends Growth
2020 3
2021 4 50%
2023 1 -300%

Boston Scientific Corporation Profile

About Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

CEO
Mr. Michael F. Mahoney
Employee
45.000
Address
300 Boston Scientific Way
Marlborough, 01752-1234

Boston Scientific Corporation Executives & BODs

Boston Scientific Corporation Executives & BODs
# Name Age
1 Mr. Jeffrey B. Mirviss
Executive Vice President & Pres of Peripheral Interventions
70
2 Mr. John Bradley Sorenson
Executive Vice President of Global Operations
70
3 Mr. Joseph M. Fitzgerald
Executive Vice President & Group Pres of Cardiology
70
4 Ms. Susan Vissers Lisa
Vice President of Investor Relations
70
5 Ms. Mary Beth Moynihan
Senior Vice President of Market Access & Chief Marketing Officer
70
6 Ms. Jodi Euerle Eddy
Senior Vice President and Chief Information & Digital Officer
70
7 Mr. Michael F. Mahoney
Chairman, Pres & Chief Executive Officer
70
8 Mr. Vance R. Brown
Senior Vice President, Gen. Counsel & Corporation Sec.
70
9 Mr. Daniel J. Brennan
Executive Vice President & Chief Financial Officer
70
10 Ms. Catherine Jennings
Vice President of Global Marketing & New Bus. Devel. of Peripheral Interventions
70
11 Mr. Jonathan R Monson
Senior Vice President, Global Controller & Chief Accounting Officer
70
12 Mr. Arthur C. Butcher
Executive Vice President and Group Pres of MedSurg & Asia Pacific
70
13 Mr. Arthur Crosswell Butcher
Executive Vice President and Group Pres of MedSurg & Asia Pacific
70

Boston Scientific Corporation Competitors